Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer

The Blood Neutrophil-to-lymphocyte Ratio Predicts Survival in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib

(2014) You-Bing Zheng et al.   Asian Pacific Journal of Cancer Prevention

The platelet–cancer loop

(2013) Hadi A. Goubran et al.   European Journal of Internal Medicine

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities

(2012) Roger B. Cohen et al.   INVESTIGATIONAL NEW DRUGS

Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer

(2012) Supachai Raungkaewmanee et al.   Journal of Gynecologic Oncology

A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study

(2011) Michael J. Proctor et al.   EUROPEAN JOURNAL OF CANCER

Platelets, inflammation and tissue regeneration

(2011) Alan Nurden   THROMBOSIS AND HAEMOSTASIS

Pretreatment Neutrophil-to-Lymphocyte Ratio as an Independent Predictor of Recurrence in Patients With Nonmetastatic Renal Cell Carcinoma

(2010) Yoshio Ohno et al.   JOURNAL OF UROLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma

(2008) Richard A. Smith et al.   AMERICAN JOURNAL OF SURGERY